Access Resources
1411 - 1420 of 7540 Results
Title
Year
-
RESTRICTEDTitle: Issue OverviewJournal Name: CONTINUUM: Lifelong Learning in NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 28Issue #: 3Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/01.con.0000840008.09408.75Citation Count: 0
- Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson’s disease2022RESTRICTEDTitle: Modulation of miR-181 influences dopaminergic neuronal degeneration in a mouse model of Parkinson’s diseaseJournal Name: Molecular Therapy - Nucleic AcidsPublisher: Elsevier BVVol: 28Issue #:Start Page: 1End Page: 15Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.omtn.2022.02.007Best OA location URL: http://www.cell.com/article/S216225312200035X/pdfCitation Count: 9
-
RESTRICTEDTitle: Molecular mechanisms defining penetrance of LRRK2-associated Parkinson’s diseaseJournal Name: Medizinische GenetikPublisher: Walter de Gruyter GmbHVol: 34Issue #: 2Start Page: 103End Page: 116Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1515/medgen-2022-2127Best OA location URL: https://www.degruyter.com/document/doi/10.1515/medgen-2022-2127/pdfCitation Count: 0
-
RESTRICTEDTitle: Pathogenic Impact of α-Synuclein Phosphorylation and Its Kinases in α-SynucleinopathiesJournal Name: International Journal of Molecular SciencesPublisher: MDPI AGVol: 23Issue #: 11Start Page: 6216End Page: 6216Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.3390/ijms23116216Best OA location URL: https://www.mdpi.com/1422-0067/23/11/6216/pdf?version=1654589185Citation Count: 24
-
RESTRICTEDTitle: Pathogenic LRRK2 regulates centrosome cohesion via Rab10/RILPL1-mediated CDK5RAP2 displacementJournal Name: iSciencePublisher: Elsevier BVVol: 25Issue #: 6Start Page: 104476End Page: 104476Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.isci.2022.104476Best OA location URL: http://www.cell.com/article/S2589004222007477/pdfCitation Count: 13
- Perry Syndrome with Intrafamilial Heterogeneity in Presentation and Survival Including Acute Respiratory Failure: Case Series2022RESTRICTEDTitle: Perry Syndrome with Intrafamilial Heterogeneity in Presentation and Survival Including Acute Respiratory Failure: Case SeriesJournal Name: Movement Disorders Clinical PracticePublisher: WileyVol: 9Issue #: 6Start Page: 816End Page: 820Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1002/mdc3.13473Best OA location URL: https://doi.org/10.1002/mdc3.13473Citation Count: 2
-
RESTRICTEDTitle: Pets May Be Good for Brain HealthJournal Name: Brain & LifePublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 18Issue #: 3Start Page: 6End Page: 7Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1097/01.nnn.0000834384.40968.7eCitation Count: 0
- Pre‐existing humoral immune comebacks control the development of the severe form of coronavirus disease 2019 in Gaucher patients2022RESTRICTEDTitle: Pre‐existing humoral immune comebacks control the development of the severe form of coronavirus disease 2019 in Gaucher patientsJournal Name: Clinical and Translational DiscoveryPublisher: WileyVol: 2Issue #: 2Start Page:End Page:Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1002/ctd2.96Best OA location URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ctd2.96Citation Count: 4
-
RESTRICTEDTitle: Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson’s diseaseJournal Name: Cell Reports MedicinePublisher: Elsevier BVVol: 3Issue #: 6Start Page: 100661End Page: 100661Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.xcrm.2022.100661Best OA location URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245058Citation Count: 45
- Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial2022RESTRICTEDTitle: Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trialJournal Name: eBioMedicinePublisher: Elsevier BVVol: 80Issue #:Start Page: 104021End Page: 104021Publication Date:Open Access(OA) Status: RESTRICTEDLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.ebiom.2022.104021Best OA location URL: http://www.thelancet.com/article/S2352396422002055/pdfCitation Count: 26